Downstream Processing Featured Articles

31. Biologists Engineer Algae To Make Complex Anti-Cancer 'Designer' Drug 12/10/2012

    Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer.

32. Pfenex Inc. Awards Althea Technologies A Contract For cGMP Manufacturing Of Circumsporozoite Protein From Plasmodium Falciparum, A Key Malaria Antigen 10/24/2012

    Pfenex Inc. recently announced that it has awarded Althea Technologies a contract for the current Good Manufacturing Practice (cGMP) manufacturing of circumsporozoite protein (CSP) from Plasmodium falciparum, an important and proven component of an effective malaria vaccine.

33. GeoVax Awarded $1.9 Million Grant By US Government For HIV/AIDS Vaccine Program 10/1/2012

    GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced receipt of a $1.9 million award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of a clade C version of the Company's current clade B vaccine products.

34. Lonza And OncoMed Pharmaceuticals Sign A Process Development And Manufacturing Collaboration And Multi-Product GS License Agreement For Anti-Cancer Therapeutics 10/23/2012

    Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced recently an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.

35. Designer Bacteria May Lead To Better Vaccines 1/15/2013

    Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

36. FDA Approves New Seasonal Influenza Vaccine Made Using Novel Technology 1/16/2013

    The U.S. Food and Drug Administration recently announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

37. Whitehead Scientists Identify Major Flaw In Standard Approach To Global Gene Expression Analysis 10/25/2012

    Whitehead Institute researchers report that common assumptions employed in the generation and interpretation of data from global gene expression analyses can lead to seriously flawed conclusions about gene activity and cell behavior in a wide range of current biological research. By Nicole Giese Rura

38. Nearly 1,000 Medicines In Development To Help Patients In Their Fight Against Cancer 5/31/2012

    America’s biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of canceraffecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

39. NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into A Cell Therapy Manufacturing Services Agreement With Adaptimmune 1/16/2013

    NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced recently a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1^c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).

40. Roche Medicine Avastin Receives EU Approval For The Treatment Of Women With Recurrent, Platinum-Sensitive Ovarian Cancer 10/31/2012

    Roche announced recently that the European Commission (EC) has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.